

1 **Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine**
2 **Expressing SARS-CoV-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial**

3 **Authors**

4 Vu Dinh Thiem MD¹, Dang Duc Anh MD¹, Vu Hai Ha MD¹, Nguyen Van Thom MD², Tran Cong Thang MD³, Jose
5 Mateus PhD⁴, Juan Manuel Carreño PhD^{5,6}, Rama Raghunandan PhD⁷, Nguyen Mai Huong BPharm³, Laina D Mercer
6 PhD⁷, Jorge Flores MD⁷, E Alexandar Escarrega MS⁴, Ariel Raskin BA^{5,6}, Duong Huu Thai MD⁸, Le Van Be MD⁸,
7 Alessandro Sette Dr.Biol.Sc ^{4,9}, Bruce L Innis MD⁷, Florian Krammer PhD^{5,6,10}, Daniela Weiskopf PhD^{4,9}

8 **Author affiliations**

9 ¹ National Institute of Hygiene and Epidemiology, 1 Yersin Street, Hai Ba Trung District, Hanoi, Vietnam

10 ² Center for Disease Control, Thai Binh Province, 10 Hoàng Công Chất street, Quang Trung ward, Thai Binh, Vietnam

11 ³ PATH Vietnam, Hanoi Towers, 49 Hai Ba Trung Street, Hoan Kiem District, Hanoi, Vietnam

12 ⁴ Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA

13 ⁵ Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, New York, NY, USA.

14 ⁶ Center for Vaccine Research and Pandemic Preparedness (C-VaRPP) at Mount Sinai New York, New York, NY,
15 USA

16 ⁷ Center for Vaccine Innovation and Access, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA.

17 ⁸ Institute of Vaccines and Medical Biologicals, 9 Pasteur, Xuong Huan, Nha Trang City, Khanh Hoa, Vietnam

18 ⁹ Department of Medicine, University of California, San Diego (UCSD), La Jolla, CA, 92037, USA

19 ¹⁰ Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New
20 York, New York, USA

21 **Correspondence to:**

22 Rama Raghunandan, <mailto:rraghunandan@path.org>, +1-301-793-6132

23 Florian Krammer, florian.krammer@mssm.edu, +1-212-241-8166

24 Daniela Weiskopf, daniela@lji.org, +1-858-752-6919

25

26

27 **Summary**

28 **Background**

29 Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and lower-middle-income countries
30 is needed. NDV-HXP-S is an inactivated egg-based recombinant Newcastle disease virus vaccine expressing the spike
31 protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A public sector manufacturer in Vietnam
32 assessed the immunogenicity of NDV-HXP-S (COVIVAC) relative to an authorized vaccine.

33 **Methods**

34 This phase 2 stage of a randomised, observer-blind, controlled, phase 1/2 trial was conducted at three community
35 health centers in Thai Binh Province, Vietnam. Healthy males and non-pregnant females, 18 years of age and older,
36 were eligible. Participants were randomised by age (18-59, ≥ 60 years) to receive one of three treatments by
37 intramuscular injection twice, 28 days apart: COVIVAC at 3 μg or 6 μg , or AstraZeneca COVID-19 vaccine
38 VAXZEVRIA. Participants and personnel assessing outcomes were masked to treatment. The main outcome was the
39 induction of 50% neutralising antibody titers against vaccine-homologous pseudotyped virus 14 days (day 43) and 6
40 months (day 197) after the second vaccination by age group. The primary immunogenicity and safety analyses
41 included all participants who received one dose of the vaccine. ClinicalTrials.gov NCT05940194.

42 **Findings**

43 During August 10-23, 2021, 737 individuals were screened, and 374 were randomised (124-125 per group); all
44 received dose one, and three missed dose two. On day 43, the geometric mean fold rise of 50% neutralising antibody
45 titers for subjects age 18-59 years was 31·20 (COVIVAC 3 μg N=82, 95% CI 25·14-38·74), 35·80 (COVIVAC 6 μg ;
46 N=83, 95% CI 29·03-44·15), 18·85 (VAXZEVRIA; N=82, 95% CI 15·10-23·54), and for subjects age ≥ 60 years was
47 37·27 (COVIVAC 3 μg ; N=42, 95% CI 27·43-50·63), 50·10 (COVIVAC 6 μg ; N=40, 95% CI 35·46-70·76), 16·11
48 (VAXZEVRIA; N=40, 95% CI 11·73-22·13). Among subjects seronegative for anti-S IgG at baseline, the day 43
49 geometric mean titer ratio of neutralising antibody (COVIVAC 6 μg /VAXZEVRIA) was 1·77 (95% CI 1·30-2·40) for
50 subjects age 18-59 years and 3·24 (95% CI 1·98-5·32) for subjects age ≥ 60 years. On day 197, the age-specific ratios
51 were 1·11 (95% CI 0·51-2·43) and 2·32 (0·69-7·85). Vaccines were well tolerated; reactogenicity was predominantly
52 mild and transient. The percentage of subjects with unsolicited adverse events (AEs) during 28 days after vaccinations
53 was similar among treatments (COVIVAC 3 μg 29·0%, COVIVAC 6 μg 23·2%, VAXZEVRIA 31·2%); no vaccine-
54 related AE was reported.

55 **Interpretation**

56 Considering that induction of neutralising antibodies against SARS-CoV-2 has been correlated with the efficacy of
57 COVID-19 vaccines, including VAXZEVRIA, our results suggest that vaccination with COVIVAC may afford
58 clinical benefit matching or exceeding that of the VAXZEVRIA vaccine.

59 **Funding**

60 Vietnam's Institute of Vaccines and Medical Biologicals (including support from Vietnam's national COVID-19
61 vaccine fund and a charitable contribution from the Thien Tam fund of Vin group), Coalition for Epidemic
62 Preparedness Innovations, a charitable contribution from Bayer AG, US National Institutes of Health.

63

64 **Introduction**

65 The coronavirus disease 2019 (COVID-19) pandemic has resulted in millions of deaths, burdened healthcare systems
66 globally, and exposed vaccine access inequities worldwide. A systematic study to assess the impact of delayed supply
67 of COVID-19 vaccines indicated that only 25% of the population in low- and lower-middle-income countries received
68 at least one dose of vaccine as of October 2022.¹ Ensuring an adequate supply of COVID-19 vaccines for low- and
69 lower-middle-income countries (LMICS), which constitute 85% of the global population, is essential.

70 As of March 2023, Vietnam's Ministry of Health recorded 11,525,408 COVID-19 cases, ranking 13th in amount of
71 cases among 230 countries and territories worldwide.² Although imported vaccines and infection-induced immunity
72 have reduced the risk of disease, the threat from new viral variants and the potential need for vaccinating elderly adults
73 and other at-risk individuals annually highlight the value to Vietnam of access to domestically produced COVID-19
74 vaccines as a sustainable asset.

75 The rapid rollout of COVID-19 vaccines saved millions of lives globally.³ By inducing potent severe acute respiratory
76 syndrome coronavirus 2 (SARS-CoV-2) antibodies, COVID-19 vaccines reduce the risk of severe disease, with the
77 level of antibodies induced correlated with vaccine efficacy.^{4,5} However, the emergence of Omicron sub-lineage
78 variants with increased transmissibility and escape from pre-existing neutralising antibodies emphasizes the
79 importance of confirming that new COVID-19 vaccine candidates also induce cellular immunity.⁶

80 PATH and the Icahn School of Medicine at Mount Sinai collaborated with Vietnam's Institute of Vaccines and
81 Medical Biologicals (IVAC), a manufacturer of egg-based inactivated influenza vaccines, to develop an egg-based
82 inactivated Newcastle disease virus vaccine expressing a six-proline prefusion-stabilized SARS-CoV-2 spike (NDV-
83 HXP-S COVID-19 vaccine, also known as COVIVAC).⁷ In a phase 1 trial (NCT04830800), COVIVAC
84 administered twice 28 days apart had an acceptable safety and immunogenicity profile in healthy adults 18-59.⁸ For
85 the next stage of clinical development, IVAC sponsored a phase 2 trial in which the safety and immunogenicity of
86 COVIVAC at two dosage levels, in adults with stable health including individuals ≥ 60 years of age, was contrasted
87 with AstraZeneca's adenovirus vectored COVID-19 vaccine (VAXZEVRIA)⁹ then the authorized pandemic vaccine
88 most commonly administered in Vietnam. The study aimed to demonstrate that COVIVAC induced a superior
89 neutralising antibody response to vaccine-homologous SARS-CoV-2 relative to VAXZEVRIA. The study also aimed
90 to explore the activation of SARS-CoV-2 spike-specific T cells by COVIVAC versus VAXZEVRIA. This report
91 provides the results of that clinical trial, including the induction of virus neutralising antibodies against pseudotyped
92 and wild-type (live virus) vaccine-homologous SARS-CoV-2 and virus-specific T-cell activation

93 **Methods**

94 **Study design and participants**

95 This phase 2 stage (NCT05940194) of a randomised, observer-blind, controlled, phase 1/2 trial was conducted at three
96 community health centers within the Vu Thu District Health Center catchment, Thai Binh Province, Vietnam.
97 Investigators from Vietnam's National Institute of Hygiene and Epidemiology (NIHE) collaborated with staff of the
98 community health centers, district health center, district hospital, and the Provincial Center for Disease Control to
99 perform the study. Participants were recruited following community outreach. Males and non-pregnant females (sex
100 or gender was self-reported) with stable health, 18 years of age and older, with body mass index 17 to 40 kg/m², with
101 no history of confirmed COVID-19 or infection with human immunodeficiency virus, were eligible to participate. A
102 negative urinary pregnancy test was required of women with reproductive capacity before administering each study
103 vaccine dose. Complete eligibility criteria are described in the trial protocol provided in the supplementary material.

104 Written informed consent was obtained from all participants. The trial complied with the Declaration of Helsinki and
105 Good Clinical Practice. This study was jointly approved by the Institutional Review Board of the Vietnam National
106 Institute of Hygiene and Epidemiology and the Independent Ethics Committee of the Vietnam Ministry of Health ref
107 no. 1407/QD-BYT.

108 **Randomisation and masking**

109 Subjects (N=374) were randomly allocated to one of three equal groups (COVIVAC 3 µg, COVIVAC 6 µg, or the
110 comparator VAXZEVRIA) using a computer-generated randomisation sequence prepared by an unblinded statistician.
111 Randomisation was age-stratified, with approximately one-third of subjects aged ≥60 years. An unmasked pharmacist
112 dispensed each treatment according to the randomisation sequence to an unmasked vaccinator. All participants and
113 study personnel, besides the unmasked pharmacy team and vaccinators, were masked for treatment.

114 **Procedures**

115 The recombinant NDV-HXP-S vaccine (COVIVAC) was manufactured according to current Good Manufacturing
116 Practice (GMP) by IVAC in their Influenza Vaccine Plant (Nha Trang, Vietnam), as previously described.⁸ The
117 adenovirus vectored vaccine from AstraZeneca (ChAdOx1; VAXZEVRIA), used as a comparator vaccine, was
118 sourced from the Ministry of Health. Unmasked vaccinators administered study treatments by intramuscular injection
119 of 0.5 mL on study days 1 and 29. Subjects were observed in the clinic for 30 min after each vaccination. Blood
120 samples were drawn for immunogenicity endpoints before vaccination on days 1 (first dose), 43 (14 days post dose
121 two), and 197 (6 months post dose two). Subjects randomly allocated to a cell-mediated immunity subset (N=12 per
122 treatment group) had additional blood collected on days 1 and 43 to isolate peripheral blood mononuclear cells
123 (PBMCs); these were stored in liquid nitrogen until analysed. Solicited injection site reactions (pain/tenderness,
124 swelling/induration, erythema) and systemic symptoms (headache, fatigue, malaise, myalgia, arthralgia,

125 nausea/vomiting, and fever defined as oral temperature $\geq 38^{\circ}\text{C}$) were recorded by subjects in a diary card for seven
126 days post-vaccination that included intensity, which the investigators then reported. Subjects also recorded unsolicited
127 adverse events (AEs) for 28 days after each vaccine dose and reported them at scheduled clinic visits, whereupon the
128 investigator included these in the study database after interviewing the subjects, grading them for intensity as
129 previously described,⁸ assessing them for causality, and categorizing them as severe or not. Severe AEs were collected
130 for the duration of the study. A Data Safety Monitoring Board (DSMB) monitored unblinded safety data.

131 We measured anti-SARS-CoV-2 spike IgG using a validated indirect enzyme-linked immunosorbent assay (ELISA)
132 at Nexelis (Laval, Canada), as described.⁸ Concentrations were transformed to binding antibody units per mL
133 (BAU/mL), based on the World Health Organization (WHO) International Standard for anti-SARS-CoV-2
134 immunoglobulin using a conversion factor determined during assay validation (1/7·9815). The assay's cut-off and
135 lower limit of quantitation (LLOQ) were 6·3 BAU/mL.

136 We measured serum neutralising activity against the Wuhan-Hu-1 strain of SARS-CoV-2 in a validated pseudotyped
137 virus neutralization assay (PNA)⁸ that assessed particle entry inhibition.¹⁰ The neutralising titer of a serum sample was
138 calculated as the reciprocal serum dilution corresponding to the 50% neutralisation antibody titer (NT₅₀) for that
139 sample; the NT₅₀ titers may be transformed to international units per mL (IU/mL), based on the WHO international
140 standard for anti-SARS-CoV-2 immunoglobulin, using a conversion factor determined during assay validation
141 (1/1·872). The assay's cut-off and lower limit of quantitation (LLOQ) were 5·3 IU/mL (10 as the NT₅₀ titer value)
142 and 5·9 IU/mL, respectively.

143 We also measured live virus neutralising activity as a 50% inhibitory dilution (ID₅₀) against a wild-type SARS-CoV-
144 2 isolate (USA-WA1/2020, catalog number NR-52281; BEI Resources) using an assay performed in a biosafety level
145 3 facility as previously described.¹¹ Briefly, Vero.E6 cells (20,000 cells/100 μL per well) were seeded onto sterile 96-
146 well cell culture plates a day prior to the neutralisation assay. Sera were serially diluted in minimal essential medium
147 (MEM; Life Technologies) at a 1:10 starting dilution. One thousand (1,000) median tissue culture infectious doses
148 (TCID₅₀s) of the virus were incubated with diluted sera for 1 hour inside a biosafety cabinet. Media from confluent
149 cell monolayers (90%) was removed, and 120 μL of the virus-serum dilutions were added to the cells for 1 h at 37°C.
150 The mixture was removed and 100 μL of each corresponding serum dilution was added per well. Additionally, 100
151 μL of MEM was added to every well. Remdesivir at 10 μM was used as control. Plates were incubated at 37°C for
152 48 hours, media was removed, and cells were fixed with 150 μL of 10% formaldehyde (Polysciences) per well. After
153 fixation, cells were permeabilized and stained using the 1C7C7 mAb.¹¹ The live virus neutralisation assay (LVNA)
154 cutoff (ID₅₀) was 1:10.

155 To assess the breadths of the adaptive immune response, we measured vaccine-induced spike-specific T cells in PBMC
156 samples utilizing a T cell receptor (TCR) dependent activation induced markers (AIM) assay.¹²⁻¹³ AIM assays have
157 been comprehensively used to compare COVID-19 vaccine-induced T cell responses.¹⁴⁻¹⁵ This assay measures antigen

158 specific T cells based on upregulation of activation markers, irrespective of cytokines.¹⁶ Antigen-specific CD4⁺ and
159 CD8⁺ T cells were measured as a percentage of AIM⁺ T cells⁺ as described before.^{14,16-17} Briefly, PBMC were thawed
160 and plated in 96-wells U-bottom plates at 1x10⁶ PBMC per well, then blocked at 37°C for 15 min with 0.5 µg/ml anti-
161 CD40 mAb (Miltenyi Biotec), and fluorescently labeled with chemokine receptor antibodies (anti-CCR6, CXCR5,
162 CXCR3, and CCR7) (see Supplement Table 1 for list of antibodies used). Cells were incubated at 37°C for 24 hrs
163 with a spike-specific peptide mega pool (MP; 1 µg/ml); controls were dimethyl sulfoxide (DMSO, an equimolar
164 amount) and phytohaemagglutinin PHA (2.5 µg/ml). The mega pool (MP) approach, previously described, enables
165 simultaneous testing of a large number of epitopes, facilitating the characterization of T-cell responses to infectious
166 diseases.¹³⁻¹⁴ We stimulated the PBMCs *ex vivo* to evaluate the antigen-specific T cell response against SARS-CoV-
167 2. The spike MP has 253 overlapping peptides spanning the entire sequence of the spike protein.¹⁸ SARS-CoV-2 spike-
168 specific circulating CD4⁺ T cells and spike-specific circulating CD8⁺ T cells were measured by surface co-expression
169 of OX40+CD137⁺ and CD69+CD137⁺, respectively. SARS-CoV-2 spike-specific circulating follicular helper T
170 (cT_{FH}) cells were measured as CXCR5+OX40+surface CD40L⁺ and quantified as a percentage of CD4⁺ T cells after
171 stimulation with spike MP. The samples were acquired on a Cytex Aurora (Cytex Biosciences). The gating strategy
172 is shown in Supplement Figure 1.

173 **Outcomes**

174 The primary outcomes were safety and induction of neutralising antibodies by COVIVAC, comparing 3 µg to 6µg
175 and each COVIVAC group to the VAXZEVRIA group. The safety of each treatment was evaluated as the number
176 and severity of solicited injection site and systemic AEs during 7 days after vaccination. Number, severity, and
177 relatedness of unsolicited (spontaneously reported) AEs during 28 days after each vaccination; and occurrence of
178 medically attended AEs, serious AEs, and AEs of special interest throughout the 7-month study period. Induction of
179 neutralising antibody measured by PNA was expressed as a geometric mean titer (GMT) at 14days post second
180 vaccination, a GMT ratio in subjects seronegative at baseline, a geometric mean fold rise (GMFR), and a percentage
181 of subjects with a ≥4-fold increase from baseline regardless of baseline anti-spike IgG seropositivity. A secondary
182 immunogenicity outcome was the induction of anti-spike IgG in binding antibody units (BAU/mL) expressed in the
183 same four parameters used for the neutralising activity. The exploratory immunogenicity outcomes were the induction
184 of neutralising antibodies to wild-type SARS-CoV-2 expressed as a GMT and GMT ratio (COVIVAC/VAXZEVRIA)
185 at 14days post second vaccination, and the frequency of spike-specific activated T cells.

186 **Statistical analysis**

187 This study (ClinicalTrials.gov NCT05940194) was descriptive with no confirmatory objective, as it was intended to
188 assess the feasibility of advancing the evaluation of COVIVAC towards emergency use authorization based on
189 superiority to the comparator. The study had >90% power to demonstrate a lower bound of the 95% confidence interval
190 (CI) of the GMT ratio greater than 1.0 if the observed ratio (COVIVAC/VAXZEVRIA) was ≥1.65. The study also
191 had >95% power to detect at least one serious or severe adverse event if the underlying rate was ≥2.5% and power

192 was >80% to detect differences in AE rates $\geq 15\%$. All statistical tests were two-sided with a significance level of 0.05.
193 All statistical analyses were performed using SAS version 9.4. All safety assessments occurred in the treatment-
194 exposed population, according to the treatment received. All treatment group percentages were supplemented with
195 two-sided 95% confidence intervals (CIs) computed via the Clopper-Pearson method. The immunogenicity analysis
196 presented was performed in the full analysis population that included all subjects randomised for whom any post-
197 vaccination immunogenicity data were available. This population is identical to the per-protocol population at Day
198 43. Geometric mean antibody responses were reported by treatment and time point, accompanied by 95% CIs. The
199 analysis of geometric means excluded subjects who were seropositive at baseline (defined by anti-spike IgG >LLOQ
200 as measured by ELISA). Geometric mean fold rises (GMFR) were calculated relative to baseline using the log
201 difference of the paired samples, with corresponding CIs computed via the t-distribution, utilizing the antilog
202 transformation to present the ratio. The proportions of subjects with GMFRs of NT50 ≥ 4 from baseline were
203 summarized with two-sided 95% confidence intervals computed via the Clopper-Pearson method. The analysis of
204 immunogenicity relative to baseline included baseline seropositive subjects. The CD4+ T cell responses were
205 summarized via the geometric mean and treatment groups were compared via the Mann-Whitney U test.

206 **Role of the funding source**

207 The funders of the study had no role in data collection, data analysis, or writing of the statistical report. IVAC was the
208 clinical trial sponsor and approved the study protocol. IVAC employees contributed as authors by preparing the
209 investigational vaccine, interpreting data, and critically reviewing this report. All authors had full access to all data in
210 the study and accepted responsibility for the decision to submit for publication.

211 Results

212 From August 10 to 23, 2021, 737 individuals were screened and 374 were randomised to three treatment groups (124-
213 125 subjects per group). All received dose one; three missed dose two; 365 completed the last study visit on day 197
214 (Figure 1). The baseline characteristics are shown by treatment group in Table 1; the exposed population was 49.5%
215 male, had a mean age of 49 years (range 18-77) and a mean body mass index of 22.29 (range 17.01-31.76).

216 Trial participants from all three vaccine groups tolerated the doses with no dose-limiting reactogenicity. Solicited
217 injection site reactogenicity was mostly mild during the seven days after each vaccination (Table 2). Pain or tenderness
218 was the most common injection site symptom recorded, more frequently following dose one than dose two. Post-dose
219 one-injection site pain was reported by 72% of VAXZEVRIA recipients but by only 46–56% of COVIVAC recipients.
220 The most common systemic symptoms (Table 2) were fatigue or malaise, headache, and myalgia, reported more
221 frequently following dose one than dose two. Notably, fever ($\geq 38^{\circ}\text{C}$) following dose one occurred in 22.4% of
222 VAXZEVRIA recipients but in only 0.8% of COVIVAC recipients. Unsolicited adverse events occurring 28 days
223 after vaccination (Supplement Table 2) were reported by a similar proportion of subjects in each treatment group
224 (23.2–31.2%); none of these events were judged by the investigator to be treatment-related or led to withdrawal from
225 the trial. Although six serious adverse events were reported during the entire study period (three in each COVIVAC
226 treatment group), none were considered treatment-related (intestinal obstruction, sialadenitis, leukemia, COVID-19,
227 colon cancer, and gastric cancer). The independent DSMB expressed no safety concerns.

228 The main immunogenicity measure was the induction of vaccine-homologous antibodies assessed by PNA 14 days
229 after vaccine dose two. Figure 2 shows plots of neutralising (PNA) antibody GMT by age and treatment group over
230 time among the 95% of subjects seronegative at baseline for anti-S IgG and with a valid assay result (see also
231 Supplement Table 3). Responses to COVIVAC were significantly higher than to VAXZEVRIA 14 days after vaccine
232 dose two, although this contrast was not statistically significant six months after vaccine dose two. Note that six
233 months after dose two, GMTs remained well above baseline, with increases in two groups among adults 18-59 years
234 of age, presumably due to intercurrent infection with SARS-CoV-2. The percentage of subjects 18-59 years of age
235 mounting a minimum four-fold PNA response to vaccination 14 days after vaccine dose two was 89.0% (95% CI
236 80.2-94.9) for COVIVAC 3 μg , 92.8% (95% CI 84.9-97.3) for COVIVAC 6 μg , and 85.4% (95% CI 75.8-92.2) for
237 VAXZEVRIA. Equally high PNA response rates were also observed in COVIVAC vaccinees ≥ 60 years of age
238 (Supplement Table 4). Notably, the magnitude of neutralising antibody induction 14 days after dose two, expressed
239 as a PNA GMFR from baseline, although similar between COVIVAC groups, was greater compared to the
240 VAXZEVRIA group (Table 3) for subjects 18-59 years of age and for subjects ≥ 60 years of age. The greater peak
241 induction of neutralising antibodies by COVIVAC relative to VAXZEVRIA was also apparent in the GMT ratios
242 (COVIVAC/VAXZEVRIA) for both dose levels with 95% confidence intervals that excluded 1.00 for both age strata
243 (Supplement Table 5).

244 To confirm the observation of COVIVAC's superior peak induction of vaccine-homologous neutralizing antibodies,
245 we evaluated the GMT of neutralising antibodies measured by live virus neutralizing assay (LVNA) induced by two
246 doses of 3µg or 6µg of COVIVAC and compared it with neutralising antibodies induced by VAXZEVRIA. Although
247 the GMTs measured by live virus assays were approximately two thirds less than mean titers measured by pseudotyped
248 virus, the GMT ratios estimated for the two COVIVAC groups relative to the VAXZEVRIA group by either assay
249 were 1.5 to 2.0-fold higher in a dose-dependent manner (Supplement Table 6).

250 A secondary immunogenicity outcome was the induction of anti-spike IgG in binding antibody units (BAU/mL). By
251 this measure of immunogenicity, VAXZEVRIA induced higher peak concentrations of anti-spike IgG measured by
252 ELISA than did COVIVAC at either dose or for both age strata (Supplement Tables 7–9). For instance, the GMC ratio
253 (COVIVAC 3µg/VAXZEVRIA) at 14 days after vaccine dose two in subjects 18-59 was 0.38 (95% CI, 0.29-0.50),
254 and in those ≥60 was 0.47 (95% CI 0.28-0.78). Six months after dose two, the 95% CI for the GMC ratios included
255 1.00. This aligns with earlier observations showing that inactivated NDV-HXP S induces higher neutralising antibody-
256 to-spike binding antibody ratios compared to other vaccine platforms.¹⁹

257 Finally, we explored the induction of spike specific CD4+ T cell responses by COVIVAC and VAXZEVRIA in a
258 random subset of vaccinated individuals with no detectable anti-spike IgG by ELISA at baseline. Spike specific CD4+
259 T cell response was assessed utilizing an activation-induced molecules (AIM) assay, which evaluates the frequency
260 of antigen-specific T cells based on the co-expression of OX40 and CD137 for CD4+ T cells and CD69 and CD137
261 of CD8+T cells (Figure 3). We detected induction of a spike specific CD4+ T cell response on day 43 in all of 10
262 COVIVAC 3 µg vaccinees with a 0.14% cell frequency (95% CI 0.074-0.27%), in 9 of 10 COVIVAC 6 µg vaccinees
263 with a 0.092% cell frequency (95% CI 0.040-0.21%), and in all of 12 VAXZEVRIA vaccinees with a 0.18% cell
264 frequency (95% CI 0.095-0.34%) (Figure 3B). The intensity of spike specific CD4+ T cell induction on day 43 was
265 similar among the treatment groups (Figure 3C).

266 Follicular helper T (T_{FH}) cells help B cells activate antibody production. As this T cell subset can be induced by SARS-
267 CoV-2 infection and COVID-19 vaccination, we evaluated the frequency of circulating T_{FH} cells by the AIM assay at
268 baseline (day 1) and post-dose two (day 43) (Figure 3E). cT_{FH} were detected on day 43 in 8 of 10 COVIVAC 3 µg
269 vaccinees with a 0.077% cell frequency (95% CI 0.020-0.097%), in 4 of 10 COVIVAC 6 µg vaccinees with a 0.044%
270 cell frequency (95% CI 0.041-0.14%), and in 9 of 12 VAXZEVRIA vaccinees with a 0.08% cell frequency (95% CI
271 0.040-0.16%) (Figure 3E). As shown for the spike specific CD4+ T cells, the intensity of spike specific cT_{FH} cells
272 induction on day 43 was similar among treatment groups (Figure 3F).

273 Antibody levels by PNA and frequencies of memory CD4+ T cells were significantly correlated for COVIVAC 3 ug
274 (r=0.824, p>0.0001), COVIVAC 6 ug (r=0.875, p>0.0001), and VAXZEVRIA (r=0.764, p>0.0001) (Figure 3G); this
275 finding is evidence of a coordinated cellular-humoral immune response in both COVIVAC and VAXZEVRIA
276 recipients.

277 Spike specific CD8⁺ T cells were also measured by AIM (CD69⁺ CD137⁺). We detected a response on day 43 in 1
278 of 10 COVIVAC 3 µg vaccinees with a 0·032% cell frequency (95% CI 0·028-0·036%), in 1 of 10 COVIVAC 6
279 µg vaccinees with a 0·037% cell frequency (95% CI 0·023-0·052%), and in 3 of 11 VAXZEVRIA vaccinees with a
280 0·049% cell frequency (95% CI 0·029-0·069%) (Figure 3H). The intensity of CD8⁺ T cell responses detected on day
281 43 was low and similar among the treatment groups. (Figure 3I).

282 Discussion

283 This phase 2 study showed that COVIVAC (NDV-HXP-S), when administered as a two-dose series to adults,
284 including those 60 years of age and older, has an acceptable safety profile. It is highly immunogenic, activating T cell
285 responses, and eliciting neutralising antibody responses 14 days after vaccine dose two that are superior to those
286 induced by the adenovirus vectored VAXZEVRIA comparator vaccine.

287 All treatments evaluated were well tolerated with predominantly mild and self-limited reactogenicity that was greater
288 after dose one than after dose two. The COVIVAC formulations at 3 and 6 µg dose levels were less reactogenic after
289 dose one than the VAXZEVRIA comparator with respect to self-reported pain at the injection site, myalgia, and
290 incidence of fever. Otherwise, there were no notable differences. Overall, in this study of 374 participants, there were
291 no spontaneously reported AEs attributed by investigators to vaccination and no concerns expressed by the DSMB
292 providing safety oversight.

293 In terms of neutralising antibody titers, measured in a PNA, both dose levels of COVIVAC showed superiority to
294 VAXZEVRIA within each age stratum at an early time point (14 days after dose two) with the trend continuing out to
295 month 6, even though statistical significance was not reached at the later time point. Superior induction of neutralizing
296 antibody by COVIVAC at both dose levels relative to VAXZEVRIA 14 days after vaccine dose two was confirmed
297 by exploratory testing using a live virus neutralization assay. Interestingly, spike-binding antibodies were lower in the
298 COVIVAC groups compared to the VAXZEVRIA group, hinting at a better ratio of neutralising to binding antibodies
299 for COVIVAC. In fact, it has been shown in an earlier study, that inactivated NDV-HXP-S vaccines induce better
300 ratios of neutralising antibodies relative to spike binding IgG compared to mRNA vaccines.¹⁹ These findings are
301 important since neutralising antibodies to SARS-CoV-2 are a mechanistic correlate of protection^{5,20} and new SARS-
302 CoV-2 vaccines (e.g. Corbevax and VLA2001) have been licensed based on immune-bridging of neutralising antibody
303 titers.²¹⁻²² Our results suggest that the possibility could be open for COVIVAC or for similar NDV-based vaccines to
304 be developed by other manufacturers.

305 There was no improvement in the induction of vaccine homologous neutralising antibodies by doubling the dose from
306 a 3 to 6 µg level. Considering the important dose effect on immunogenicity observed in the phase 1 trial comparing
307 10 and 3 µg dose levels, with no adverse impact on reactogenicity, further development of COVIVAC will likely
308 revert to a 10 µg dose level.⁸

309 In this comparative study, spike specific CD4+ T cell responses were detected in 90-100% of a small subset of
310 randomly selected individuals, all being seronegative for anti-spike IgG pre-vaccination, in test and comparator
311 vaccine groups. This is comparable to what has been reported for other COVID-19 vaccines such as mRNA and
312 adenovirus vector vaccines.¹⁴ Similarly, we have detected circulating T follicular helper cells in a substantial fraction
313 of vaccinees, supported by the strong correlation of spike-specific CD4+ T cell responses and functional antibody

314 responses. In previous studies, we demonstrated that a coordinated cellular-humoral immune response is associated
315 with mild disease outcomes in infected individuals.^{14,18.}

316 This study has several limitations. First, it was a phase 2 trial of limited size with no clinical endpoint. Second, the
317 investigational and comparator vaccines expressed an ancestral spike immunogen. Moreover, the study population
318 was largely naïve to SARS-CoV-2 at the time they were vaccinated. Currently, COVID-19 vaccines are being
319 deployed for booster immunization in primed but at risk adults. While COVIVAC performed well by inducing
320 neutralising antibodies, its use as a booster vaccine is yet to be evaluated. Vaccines with ancestral spike antigens are
321 obsolete now due to emergence of different variants, especially the Omicron variant family. Current recommendations
322 from regulatory authorities and WHO state that XBB-lineage spike antigens should be used in updated vaccines. GMP
323 seed viruses for COVIVAC with XBB.1.5 spike exist and can be used for manufacturing of strain-changed updated
324 vaccines. We did not evaluate induction of neutralising antibodies to vaccine heterologous variants, as this was outside
325 of the scope of this study. Nevertheless, we observed that COVIVAC induced CD4+ T cell responses comparable to
326 the VAXZEVRIA comparator, and it has been reported that CD4+ T cell responses induced by the ancestral spike
327 protein are maintained and cross-recognize SARS-CoV-2 variants, from Alpha to Omicron.^{23,24}

328 Strengths of this study are the use of a fully validated functional antibody readout (PNA), the inclusion of older adults
329 with an age-stratified analysis showing preservation of immunogenicity despite increased age, the assessment of T
330 cell responses, and the selection of the VAXZEVRIA vaccine as a highly relevant immuno-bridging comparator. The
331 efficacy of the VAXZEVRIA vaccine has been demonstrated in multiple double-blind randomized clinical trials,
332 varying from approximately 70% against any symptomatic disease to >95% against severe disease and/or
333 hospitalization.²⁵ Multiple effectiveness and observational studies confirmed the high level of protection afforded by
334 the vaccine, leading to its approval in the UK and other European countries.²⁶ By early 2022, the VAXZEVRIA
335 vaccine had been approved by over 170 countries, including Vietnam, making it the most widely deployed vaccine
336 across the globe with over 2.5 billion doses used.²⁶ The induction of superior levels of neutralizing antibodies by
337 COVIVAC and similar activation of CD4+ T cells in comparison to VAXZEVRIA strongly suggest that COVIVAC's
338 effectiveness would be at least similar.

339 The CD4+ and CD8+ T cell response has been assessed using the AIM assay measuring the frequency of spike-specific
340 T cell responses. It is important to point out that functional capacity of T cell responses, such as through production
341 of cytokines, need to be assessed for a comprehensive picture of vaccine-induced spike-specific T-cell responses.²⁷

342 The clinical trial was designed to assess the feasibility of conducting a phase 3 trial in which the benefit of vaccination
343 with COVIVAC could be confirmed by demonstrating non-inferior or superior immunogenicity relative to an
344 authorized comparator COVID-19 vaccine. That aim was met. Further development of COVIVAC updated to express
345 a contemporary recombinant spike protein, administered as a booster dose to vulnerable individuals, is a viable option
346 for its manufacturer IVAC, which serves the public sector of Vietnam.

347 **Contributors**

348 VDT and LDM verified the underlying data reported herein. All authors had full access to all the data in the study and
349 had final responsibility for the decision to submit for publication. Individual author roles are reported using CRediT:
350 Conceptualisation, TCT, NMH, LDM, DHT, LVB, BLI, FK, DW; Data curation, VDT, DDA, VHH, NVT, TCT, JM,
351 JMC, NMH, LDM, JF, DHT, DW; Formal analysis, LDM; Funding acquisition, RR, LVB, AS, BLI, FK, DW;
352 Investigation, VDT, DDA, VHH, NVT, JM, JMC, EAE, AR, DW; Methodology, RR, LDM, JF, FK, DW; Project
353 administration, TCT, NMH, DHT, LVH; Resources, VDT, DDA, NVT, AS, FK, DW; Supervision, VDT, DDA, JM,
354 JMC, RR, BLI, FK, DW; Validation, LDM; Visualisation, BLI; Writing-original draft, RR, BLI, FK, DW;
355 Writing-review & editing, VDT, DDA, VHH, NVT, TCT, JM, JMC, NMH, LDM, JF, EAE, AR, DHT, LVB, AS.

356 **Declaration of interests**

357 The vaccine administered in this study was developed by faculty members at the Icahn School of Medicine at Mount
358 Sinai including FK. Mount Sinai is seeking to commercialize this vaccine; therefore, the institution and its faculty
359 inventors could benefit financially. The Icahn School of Medicine at Mount Sinai has filed patent applications relating
360 to SARS-CoV-2 serological assays (U.S. Provisional Application Numbers: 62/994,252, 63/018,457, 63/020,503 and
361 63/024,436) and NDV-based SARS-CoV-2 vaccines (U.S. Provisional Application Number: 63/251,020) which list
362 FK as co-inventor. Patent applications were submitted by the Icahn School of Medicine at Mount Sinai. Mount Sinai
363 has spun out a company, Kantaro, to market serological tests for SARS-CoV-2 and another company, CastleVax, to
364 commercialize SARS-CoV-2 vaccines. FK serves on the scientific advisory board of CastleVax. FK has consulted for
365 Merck, Seqirus, Curevac and Pfizer, and is currently consulting for Gritstone, Third Rock Ventures, GSK and Avimex.
366 The FK laboratory has been collaborating with Pfizer on animal models of SARS-CoV-2. DW is a consultant for
367 Moderna. AS is a consultant for Gritstone Bio, Flow Pharma, Moderna, AstraZeneca, Qiagen, Fortress, Gilead, Sanofi,
368 Merck, RiverVest, MedaCorp, Turnstone, NA Vaccine Institute, Emervax, Gerson Lehrman Group and
369 Guggenheim.LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work.

370 **Data Sharing**

371 The study protocol is provided in the supplement. Deidentified participant data will be made available for two years
372 after publication upon request directed to the lead author Vu Dinh Thiem (vdt@nihe.org.vn). After approval of a data-
373 sharing proposal, data can be shared through a secure online platform.

374 **Acknowledgments**

375 Work at Mount Sinai was supported by philanthropic donations to Mount Sinai/institutional funding (C-VaRPP
376 funding). Preclinical development of the COVIVAC vaccine was supported, in part, by the Bill & Melinda Gates
377 Foundation [INV-021239]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0
378 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this

379 submission. Initial work on COVIVAC was also supported by institutional funding from the Icahn School of Medicine
380 at Mount Sinai. This work has been partially supported by the National Institutes of Health under Contract No.
381 75N93019C00065 to A.S, D.W. PATH was also supported by the Coalition for Epidemic Preparedness and a
382 charitable contribution from Bayer AG. We thank the University of Texas at Austin for granting IVAC access to their
383 6-proline stabilized SARS-CoV-S (Hexapro) technology.

384 **References**

- 385 1. Duroseau B, Kipshidze N, Limaye RJ. The impact of delayed access to COVID-19 vaccines in low- and
386 lower-middle-income countries. *Front Public Health*. 2022; 10:1087138.
- 387 2. Ministry of Health portal. COVID-19 epidemic prevention bulletin dated 3/1 of the Ministry of Health.
388 Ministry of Health [Internet]. 2023 Mar 1 [cited 2023 Jun 27]; Available from: [https://moh.gov.vn/tin-tong-](https://moh.gov.vn/tin-tong-hop/-/asset_publisher/k206Q9qkZOqn/content/ban-tin-phong-chong-dich-covid-19-ngay-3-1-cua-bo-y-te)
389 [hop/-/asset_publisher/k206Q9qkZOqn/content/ban-tin-phong-chong-dich-covid-19-ngay-3-1-cua-bo-y-te](https://moh.gov.vn/tin-tong-hop/-/asset_publisher/k206Q9qkZOqn/content/ban-tin-phong-chong-dich-covid-19-ngay-3-1-cua-bo-y-te)
- 390 3. World Health Organization. WHO releases global COVID-19 vaccination strategy update to reach
391 unprotected. World Health Organization [Internet]. 2022 Jul 22; Available from:
392 [https://www.who.int/news/item/22-07-2022-who-releases-global-covid-19-vaccination-strategy-update-to-](https://www.who.int/news/item/22-07-2022-who-releases-global-covid-19-vaccination-strategy-update-to-reach-unprotected)
393 [reach-unprotected](https://www.who.int/news/item/22-07-2022-who-releases-global-covid-19-vaccination-strategy-update-to-reach-unprotected)
- 394 4. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels
395 are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med*. 2021
396 Jul;27(7):1205–11.
- 397 5. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune correlates analysis
398 of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science*. 2022 Jan 7;375(6576):43–50.
- 399 6. Tarke A, Coelho CH, Zhang Z, Dan JM, Yu ED, Methot N, et al. SARS-CoV-2 vaccination induces
400 immunological T cell memory able to cross-recognize variants from Alpha to Omicron. *Cell*. 2022 Mar
401 3;185(5):847-859.e11.
- 402 7. Sun W, Liu Y, Amanat F, González-Domínguez I, McCroskery S, Slamanig S, et al. A Newcastle disease
403 virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. *Nat*
404 *Commun*. 2021 Oct 27;12(1):6197.
- 405 8. Duc Dang A, Dinh Vu T, Hai Vu H, Thanh Ta V, Thi Van Pham A, Thi Ngoc Dang M, et al. Safety and
406 immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike:
407 Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. *Vaccine*. 2022 Jun
408 9;40(26):3621–32.
- 409 9. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the
410 ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised
411 controlled trials in Brazil, South Africa, and the UK. *The Lancet*. 2021 Jan;397(10269):99–111.
- 412 10. Bewley KR, Coombes NS, Gagnon L, McInroy L, Baker N, Shaik I, et al. Quantification of SARS-CoV-2
413 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped
414 virus neutralization assays. *Nat Protoc*. 2021 Jun;16(6):3114–40.
- 415 11. Carreño JM, Alshammary H, Singh G, Raskin A, Amanat F, Amoako A, et al. Evidence for retained spike-
416 binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA
417 vaccine recipients. *EBioMedicine*. 2021 Nov;73:103626.
- 418 12. Havenar-Daughton C, Reiss SM, Carnathan DG, Wu JE, Kendric K, Torrents de la Peña A, et al. Cytokine-
419 Independent Detection of Antigen-Specific Germinal Center T Follicular Helper Cells in Immunized
420 Nonhuman Primates Using a Live Cell Activation-Induced Marker Technique. *The Journal of Immunology*.
421 2016 Aug 1;197(3):994–1002.

- 422 13. Reiss S, Baxter AE, Cirelli KM, Dan JM, Morou A, Daigneault A, et al. Comparative analysis of activation
423 induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells. *PLoS One*. 2017
424 Oct 24;12(10):e0186998.
- 425 14. Zhang Z, Mateus J, Coelho CH, Dan JM, Moderbacher CR, Gálvez RI, et al. Humoral and cellular immune
426 memory to four COVID-19 vaccines. *Cell*. 2022 Jul 7;185(14):2434-2451.e17.
- 427 15. Ogbunude POJ. Efflux of 3H-thymidine by erythrocytes from mice infected with *Trypanosoma brucei brucei*.
428 *Ann Trop Med Parasitol*. 1986 Dec 15;80(6):581–5.
- 429 16. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2
430 assessed for up to 8 months after infection. *Science*. 2021 Feb 5;371(6529).
- 431 17. Mateus J, Dan JM, Zhang Z, Rydyznski Moderbacher C, Lammers M, Goodwin B, et al. Low-dose mRNA-
432 1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. *Science*. 2021 Oct
433 22;374(6566):eabj9853.
- 434 18. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses
435 to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell*. 2020
436 Jun;181(7):1489-1501.e15.
- 437 19. Carreño JM, Raskin A, Singh G, Tcheou J, Kawabata H, Gleason C, et al. An inactivated NDV-HXP-S
438 COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination.
439 *Sci Transl Med*. 2023 Feb 15;15(683).
- 440 20. Goldblatt D, Fiore-Gartland A, Johnson M, Hunt A, Bengt C, Zavadka D, et al. Towards a population-based
441 threshold of protection for COVID-19 vaccines. *Vaccine*. 2022 Jan;40(2):306–15.
- 442 21. European Medicines Agency. COVID-19 Vaccine (inactivated, adjuvanted) Valneva [Internet]. 2022.
443 Available from: [https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-inactivated-](https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-inactivated-adjuvanted-valneva#safety-updates-section)
444 [adjuvanted-valneva#safety-updates-section](https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-inactivated-adjuvanted-valneva#safety-updates-section)
- 445 22. Biological E. Limited. Summary of Product Characteristics (SmPC) SARS-CoV-2 (Covid-19) Vaccine
446 CORBEVAX™ [Internet]. 2022 Feb. Available from:
447 <https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadSmPC/ebio.pdf>
- 448 23. Grifoni A, Sette A. From Alpha to omicron: The response of T cells. *Current Research in Immunology*.
449 2022;3:146–50.
- 450 24. Petrone L, Sette A, de Vries RD, Goletti D. The Importance of Measuring SARS-CoV-2-Specific T-Cell
451 Responses in an Ongoing Pandemic. *Pathogens*. 2023 Jun 22;12(7):862.
- 452 25. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose
453 administration and the influence of the timing of the booster dose on immunogenicity and efficacy of
454 ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *The Lancet*. 2021
455 Mar;397(10277):881–91.
- 456 26. United Kingdom Department of Health and Social Care, Javid S, Troup M. One year anniversary of UK
457 deploying Oxford-AstraZeneca vaccine. 2022 Jan 4; Available from:
458 <https://www.gov.uk/government/news/one-year-anniversary-of-uk-deploying-oxford-astrazeneca-vaccine>
- 459 27. Zhang Z, Mateus J, Coelho CH, Dan JM, Moderbacher CR, Gálvez RI, Cortes FH, Grifoni A, Tarke A, Chang
460 J, Escarrega EA, Kim C, Goodwin B, Bloom NI, Frazier A, Weiskopf D, Sette A, Crotty S. Humoral and

461 cellular immune memory to four COVID-19 vaccines. Cell. 2022 Jul 7;185(14):2434-2451.e17. doi:
462 10.1016/j.cell.2022.05.022.

463

464 **Tables**

465 **Table 1: Baseline characteristics of the exposed population**

Baseline Characteristics	COVIVAC		VAXZEVRIA
	3 µg (N = 124)	6 µg (N = 125)	(N = 125)
Mean age in years (SD; range)	48·9 (14·82; 18, 75)	48·9 (14·27; 18,77)	49·8 (14·17; 18,74)
Male	64 (51·6%)	67 (53·6%)	54 (43·2%)
Female	60 (48·4%)	58 (46·4%)	71 (56·8%)
Mean body mass index in kg/m ² (SD; range)	22·29 (2·57; 17·01, 31·76)	22·27 (2·67; 17·33, 28·75)	22·24 (2·55; 17·08, 28·88)

466

467 **Table 2: Number of subjects with solicited adverse events during 7 days after vaccination in the safety analysis**
 468 **population.**

Reaction		COVIVAC		VAXZEVRIA
		3 µg (N = 124) n (%) (95% CI*)	6 µg (N = 125) n (%) (95% CI*)	(N = 125) n (%) (95% CI*)
Pain/tenderness	Dose 1	57 (46.0%) (37.0-55.1)	65 (52.0%) (42.9-61.0)	90 (72.0%) (63.3-79.7)
	Dose 2	34 (27.4%) (19.8-36.2)	48 (39.0%) (30.4-48.2)	37 (29.8%) (22.0-38.7)
Swelling/induration	Dose 1	2 (1.6%) (0.2-5.7)	1 (0.8%) (0.0-4.4)	1 (0.8%) (0.0-4.4)
	Dose 2	2 (1.6%) (0.2-5.7)	0 (0%) (0.0-3.0)	0 (0%) (0.0-2.9)
Erythema	Dose 1	0 (0%) (0.0-2.9)	0 (0%) (0.0-2.9)	1 (0.8%) (0.0-4.4)
	Dose 2	1 (0.8%) (0.0-4.4)	0 (0%) (0.0-3.0)	0 (0%) (0.0-2.9)
Fever (≥ 38 °C)	Dose 1	1 (0.8%) (0.0-4.4)	1 (0.8%) (0.0-4.4)	28 (22.4%) (15.4-30.7)
	Dose 2	3 (2.4%) (0.5-6.9)	3 (2.4%) (0.5-7.0)	2 (1.6%) (0.2-5.7)
Headache	Dose 1	31 (25.0%) (17.7-33.6)	52 (41.6%) (32.9-50.8)	63 (50.4%) (41.3-59.5)
	Dose 2	28 (22.6%) (15.6-31.0)	28 (22.8%) (15.7-31.2)	26 (21.0%) (14.2-29.2)
Fatigue/malaise	Dose 1	53 (42.7%) (33.9-51.9)	59 (47.2%) (38.2-56.3)	77 (61.6%) (52.5-70.2)
	Dose 2	39 (31.5%) (23.4-40.4)	38 (30.9%) (22.9-39.9)	40 (32.3%) (24.1-41.2)
Myalgia	Dose 1	24 (19.4%) (12.8-27.4)	26 (20.8%) (14.1-29.0)	47 (37.6%) (29.1-46.7)
	Dose 2	21 (16.9%) (10.8-24.7)	14 (11.4%) (6.4-18.4)	23 (18.5%) (12.1-26.5)
Arthralgia	Dose 1	23 (18.5%) (12.1-26.5)	17 (13.6%) (8.1-20.9)	31 (24.8%) (17.5-33.3)
	Dose 2	5 (4.0%) (1.3-9.2)	9 (7.3%) (3.4-13.4)	16 (12.9%) (7.6-20.1)
Nausea/vomiting	Dose 1	10 (8.1%) (3.9-14.3)	9 (7.2%) (3.3-13.2)	13 (10.4%) (5.7-17.1)
	Dose 2	2 (1.6%) (0.2-5.7)	4 (3.3%) (0.9-8.1)	3 (2.4%) (0.5-6.9)

469

470 **Table 3: Summary of geometric mean fold rise (GMFR) from baseline of NT₅₀ titers against SARS-CoV-2**
 471 **pseudovirus by age group in the full analysis population**

NT50 MEASURE			COVIVAC		VAXZEVRIA
			3 µg (N = 124)	6 µg (N = 125)	(N = 125)
14 days after the second vaccination (D43)	18-59 yr.	GMFR from baseline (95% CI)	n = 82	n = 83	n = 82
			31.20 (25.14, 38.74)	35.80 (29.03, 44.15)	18.85 (15.10, 23.54)
	≥ 60 yr.	GMFR from baseline (95% CI)	n = 42	n = 40	n = 40
			37.27 (27.43, 50.63)	50.10 (35.46, 70.76)	16.11 (11.73, 22.13)
6 months after the second vaccination (D197)	18-59 yr.	GMFR from baseline (95% CI)	n = 80	n = 82	n = 80
			39.94 (21.56, 73.98)	32.27 (17.73, 58.72)	22.63 (13.72, 37.34)
	≥ 60 yr.	GMFR from baseline (95% CI)	n = 40	n = 37	n = 37
			18.31 (7.73, 43.32)	22.52 (9.26, 54.76)	13.36 (5.61, 31.82)

472

473 **Figure legends**

474 **Figure 1. Cohort disposition:** Disposition of subjects recruited and randomized in Phase 2

475 **Figure 2. Geometric mean titer and 95% CI of NT50 against SARS-CoV-2 pseudotyped virus by age and**
476 **treatment group in the full analysis population:** (a) 18-59 years, (b) ≥ 60 years

477 **Figure 3. SARS-CoV-2 spike-specific CD4+ T cell responses are induced by COVIVAC .** (A) FACS example of
478 SARS-CoV-2 spike-specific CD4+ T cells evaluated by the AIM assay after stimulation with spike MP. Spike-specific
479 CD4+ T cells were quantified by AIM (surface OX40+CD137+) after stimulation with spike peptide megapool (MP).
480 (B) Frequencies of SARS-CoV-2 spike-specific CD4+ T cells induced by COVIVAC at 3 μg and 6 μg and
481 VAXZEVRIA at day 1 (baseline) and at day 43 post-vaccination. (C) Comparison of spike specific CD4+ T cells
482 induced by COVIVAC at 3 μg and 6 μg and VAXZEVRIA at 43 days post-vaccination. (D) FACS example of SARS-
483 CoV-2 spike-specific circulating follicular helper T (cTFH) cells (CXCR5+OX40+surface CD40L+, as a percentage
484 of CD4+ T cells) after stimulation with spike MP. (E) Frequencies of SARS-CoV-2 spike-specific cTFH cells induced
485 by COVIVAC at 3 μg and 6 μg and VAXZEVRIA at day 1 (baseline) and at day 43 post-vaccination. (F) Comparison
486 of spike-specific cTFH cells induced by COVIVAC at 3 μg and 6 μg and VAXZEVRIA at 43 days post-vaccination.
487 Dotted green lines indicate the limit of quantification (LOQ). Light gray, COVIVAC at 3 μg ; red, COVIVAC at 6 μg ;
488 black, VAXZEVRIA. G) Correlation of spike specific CD4 T cell responses and neutralizing antibody titers measured
489 43 days post-vaccination for COVIVAC at 3 μg (grey line) and 6 μg (red line) and VAXZEVRIA (black line). H)
490 Comparison of spike specific CD8+ T cells induced by COVIVAC at 3 μg and 6 μg and VAXZEVRIA at 43 days
491 post-vaccination. I) Comparison of spike specific CD8+ T cells s induced by COVIVAC at 3 μg and 6 μg and
492 VAXZEVRIA at 43 days post-vaccination. The bars in (B, C, E, F, H, I) indicate the geometric mean and geometric
493 SD in the analysis of the spike-specific T cell frequencies. Data were analysed for statistical significance using the
494 Mann-Whitney U test (B, C, E, F, H, I). Background- subtracted and log data analysed in all cases.

495 **Figure S1: Gating strategy to identify CD4 and CD8 T lymphocytes:** Representative gating strategy to define
496 CD3+CD4+ and CD3+CD8+ cells by AIM assay.

497

Figure 1: Cohort disposition




Figure 2: Geometric Mean Titer and 95% CI of NT50 against SARS-CoV-2 pseudovirus by age in the full analysis population: (A) 18-59 years, (B) ≥ 60 years





Figure 3: SARS-CoV-2 spike-specific CD4⁺ T cell responses are induced by COVIVAC .



Supplement figure S1: Gating strategy

